Drugs / Omega-3 Ethyl Esters
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06434948 | Mar → Apr 2026 | delirium | University of Missouri-Columbia | Terminated | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT00931879 Comparator | Oct 2009 → Jul 2012 | diabetic neuropathy, hypertriglyceridemia | Eastern Virginia Medical School | Completed | No outcome recorded |
| Phase 4 | NCT00135226 Comparator | Mar 2005 → Mar 2018 overdue | diabetes mellitus | University of Oxford | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | omega-3-ethyl esters | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00931879 ↗ |
| Route | Oral | “Patients will be given 4 grams of omega-3 ethyl esters orally before surgery and for 3 days postoperatively.” NCT06434948 ↗ |